Global Strontium-82 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Strontium-82 market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
In 2025, global Strontium-82 production was approximately 57 grams, with an average global market price of around $73,000 per gram. Total global production capacity for Strontium-82 reached approximately 120 grams that year. The average gross profit margin for the industry is approximately 66%. Strontium-82 (Sr-82) is an artificial radioactive isotope—specifically a radionuclide of the element strontium—with an atomic number of 38 and a mass number of 82. Rather than being a radiopharmaceutical used directly in clinical applications, Sr-82 serves as a crucial parent radionuclide for the production of Rubidium-82 (Rb-82), a positron-emitting radionuclide. Sr-82 decays into Rb-82 via electron capture; while Sr-82 has a half-life of approximately 25.36 days, Rb-82 has a half-life of only about 75 seconds. Consequently, Sr-82 is typically loaded into specialized generators (Sr-82/Rb-82 generators) to facilitate the continuous production of Rb-82. Because Rb-82 emits positrons, it is utilized in positron emission tomography (PET) for myocardial perfusion imaging, making Sr-82 a vital medical isotope for diagnosing cardiovascular diseases in the field of nuclear medicine. Compared to traditional nuclear medicine isotopes like Technetium-99m (Tc-99m), the Sr-82/Rb-82 system offers advantages such as eliminating the need for on-site cyclotron production and enabling rapid PET examinations, thereby holding significant clinical value in cardiovascular diagnostic imaging.
The upstream segment of the Sr-82 industry chain primarily encompasses the supply of target materials, high-energy particle accelerator facilities, and radiochemical production systems. As there are no naturally occurring, exploitable sources of Sr-82, commercial supply relies on artificial production. The prevailing production method involves bombarding enriched Molybdenum-82 (Mo-82) targets with high-energy proton beams to generate Sr-82 through nuclear reactions; the product then undergoes chemical separation, purification, and quality testing to yield medical-grade Sr-82. While some production routes utilize alternative nuclear reaction systems—such as those employing krypton gas or rubidium targets—accelerator-based production currently dominates the medical supply chain. Given that Sr-82 production requires large-scale cyclotrons, high-purity isotopic targets, radiochemical processing facilities, and rigorous radiation safety protocols, the number of institutions capable of stable commercial supply is limited, resulting in high barriers to entry for the industry. The midstream sector primarily encompasses the radiochemical purification of Strontium-82 (Sr-82), activity testing, pharmaceutical-grade quality control, and the manufacturing of Sr-82/Rubidium-82 (Rb-82) generators. Manufacturers must ensure that Sr-82 exhibits high radiochemical purity, low levels of impurity nuclides, and stable decay characteristics to meet the requirements of clinical PET imaging. Once purified, Sr-82 is typically encapsulated within a column-type generator—combined with adsorbent materials such as alumina—allowing for the continuous production of Rb-82 injection solution via saline elution at the hospital site. Given that Sr-82 has a half-life of approximately 25 days, generators require periodic replacement, establishing a long-term supply chain model involving isotope producers, generator suppliers, and medical institutions. Currently, global supply is concentrated among nuclear facilities capable of producing medical isotopes, commercial radiopharmaceutical companies, and specialized nuclear medicine suppliers. The primary application of Sr-82 is in PET myocardial perfusion imaging. The Rb-82 produced by the Sr-82/Rb-82 generator is used to assess myocardial blood flow perfusion, aiding physicians in evaluating coronary artery disease, myocardial ischemia, and cardiovascular risk. Because Rb-82 has an extremely short half-life, patients are exposed to lower radiation doses, and dynamic image acquisition can be completed rapidly, making it particularly suitable for high-throughput cardiac PET examinations. Furthermore, driven by the aging global population, rising incidences of cardiovascular disease, and advancements in precision medicine and molecular imaging technologies, the demand for high-performance diagnostic nuclear medicine isotopes continues to grow. Looking ahead, the Sr-82 market will continue to evolve alongside the widespread adoption of nuclear medicine imaging equipment, the establishment of PET centers, improvements in isotope supply stability, and the optimization of generator technology.
As the parent radionuclide of rubidium-82 (^82Rb), strontium-82 is a critical raw material for producing Sr-82/Rb-82 generators. Rubidium-82, characterized by a short half-life of approximately 75 seconds and positron-emitting properties, is widely used in PET myocardial perfusion imaging for the assessment of coronary artery disease, myocardial ischemia, and cardiovascular risk. Driven by the aging global population, the rising number of patients with cardiovascular diseases, and rapid advancements in precision medicine and molecular imaging, the demand from medical institutions for highly efficient and safe PET diagnostic radionuclides continues to grow, providing a stable impetus for the strontium-82 market.
The widespread adoption of PET imaging technology and the expansion of nuclear medicine infrastructure have driven the growth of both supply and demand for strontium-82. Compared to traditional cardiovascular examination methods, PET myocardial perfusion imaging offers advantages such as high image resolution, robust quantitative analysis capabilities, and rapid procedural workflows, making it particularly suitable for assessing patients with complex cardiovascular conditions. As North America, Europe, and parts of the Asia-Pacific region continue to deploy PET/CT equipment, establish nuclear medicine centers, and standardize the clinical application of radiopharmaceuticals, the scope of Sr-82/Rb-82 generator usage is steadily expanding. Simultaneously, the increasing demand from medical institutions for solutions that provide a stable, long-term supply of positron-emitting radionuclides—without the need for on-site cyclotron production—has further underscored the importance of strontium-82 as a key parent isotope.
The future of the strontium-82 industry will be characterized by a trend toward a centralized supply system, upgraded production technologies, and the coordinated development of the medical isotope industry chain. Given that strontium-82 production relies on high-energy cyclotrons, enriched target materials, complex radiochemical separation processes, and strict regulatory frameworks, the industry is unlikely to adopt a model of mass industrial-scale production; instead, it will maintain a competitive landscape dominated by a limited number of enterprises and research institutions possessing the necessary nuclear facilities and radiopharmaceutical production capabilities. Future competition will focus on improving target material utilization, increasing strontium-82 yields, reducing impurity radionuclide levels, and enhancing the stability of global supply.
Report Scope
This report is a detailed and comprehensive analysis for global Strontium-82 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Strontium-82 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Strontium-82 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Strontium-82 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Strontium-82 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Strontium-82
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Strontium-82 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include NIDC(DOE IP), LANL(Los Alamos National Lab), Manhattan Isotope Technology LLC, Nordion Canada Inc., BNL(Brookhaven National Laboratory), iThemba LABS(IBA RadioPharma Solutions), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Strontium-82 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Activity Concentration＜50mCi/mL
Activity Concentration≥50mCi/mL
Market segment by Production Route
Proton Bombardment of Molybdenum-82 Target
Krypton-82 Nuclear Reaction
Market segment by Purity Grade
Research-grade Strontium-82
Medical-grade Strontium-82
Market segment by Chemical Form
Strontium Ion Solution
Solid Strontium Compound
Market segment by Application
Nuclear Medicine
Scientific Research
Major players covered
NIDC(DOE IP)
LANL(Los Alamos National Lab)
Manhattan Isotope Technology LLC
Nordion Canada Inc.
BNL(Brookhaven National Laboratory)
iThemba LABS(IBA RadioPharma Solutions)
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Strontium-82 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Strontium-82, with price, sales quantity, revenue, and global market share of Strontium-82 from 2021 to 2026.
Chapter 3, the Strontium-82 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Strontium-82 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Strontium-82 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Strontium-82.
Chapter 14 and 15, to describe Strontium-82 sales channel, distributors, customers, research findings and conclusion.